Last reviewed · How we verify
Kineret® (Anakinra)
Anakinra is a recombinant interleukin-1 receptor antagonist that blocks IL-1 signaling to reduce inflammation.
Anakinra is a recombinant interleukin-1 receptor antagonist that blocks IL-1 signaling to reduce inflammation. Used for Rheumatoid arthritis, Neonatal-onset multisystem inflammatory disease (NOMID), Deficiency of interleukin-1 receptor antagonist (DIRA).
At a glance
| Generic name | Kineret® (Anakinra) |
|---|---|
| Sponsor | Amgen |
| Drug class | Interleukin-1 receptor antagonist |
| Target | IL-1 receptor type I |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
Anakinra competitively inhibits the binding of interleukin-1 (IL-1) to the IL-1 type I receptor, preventing the pro-inflammatory effects of IL-1. By blocking this key inflammatory cytokine, it reduces the production of other inflammatory mediators and decreases immune cell activation, thereby suppressing the inflammatory cascade in autoimmune and autoinflammatory conditions.
Approved indications
- Rheumatoid arthritis
- Neonatal-onset multisystem inflammatory disease (NOMID)
- Deficiency of interleukin-1 receptor antagonist (DIRA)
Common side effects
- Injection site reactions
- Headache
- Nausea
- Diarrhea
- Infections
Key clinical trials
- IL-1 Inhibition in Early TNBC (PHASE2)
- Empagliflozin and Anakinra for the Treatment of Postprandial Hypoglycemia in Patients With Prediabetes (PHASE2)
- ANAKINRA IN THE TREATMENT OF PEDIATRIC ACUTE MYOCARDITIS (PHASE3)
- Anakinra Pilot 2 - A Study to Optimise Dose and Route of Administration of Anakinra in Preterm Infants (PHASE2)
- A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity (PHASE2)
- Pre-emptive Anakinra for Cytokine Event Reduction (PHASE1, PHASE2)
- CORIMUNO-ANA: Trial Evaluating Efficacy Of Anakinra In Patients With Covid-19 Infection (PHASE2)
- IL-1-receptor Antagonist During Cephalic Phase of Insulin Secretion in Health and Type 2 Diabetes (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Kineret® (Anakinra) CI brief — competitive landscape report
- Kineret® (Anakinra) updates RSS · CI watch RSS
- Amgen portfolio CI